<DOC>
	<DOCNO>NCT00614991</DOCNO>
	<brief_summary>To date , study investigate whether drug interaction protease inhibitor fosamprenavir integrase inhibitor raltegravir . COL111242 randomize , open-label , 6-arm , 3-period , drug interaction study ass steady-state plasma amprenavir ( APV ) raltegravir ( RTG ) pharmacokinetics 48 healthy , HIV-negative adult administration 7-day regimen RTG 400mg twice day ( BID ) alone 14-day regimen unboosted fosamprenavir ( FPV ) 1400mg twice daily ( BID ) , FPV 700mg/Ritonavir ( RTV ) 100mg BID , FPV 1400mg/ritonavir ( RTV ) 100mg daily ( QD ) without concurrent RTG 400mg BID . Blood sample drug concentration measurement collect 12 hour end dose period . Subjects undergo physical examination , complete blood count ( CBC ) differential , HIV test , hepatitis B/C test , liver function test , renal function analysis , lipid panel screening , test , except HIV hepatitis B/C , repeat follow-up post-study . Adverse event adherence ( pill count medication diary ) assess investigator/study personnel end dose period</brief_summary>
	<brief_title>An Interaction Study Assess Drug Levels Healthy Adult Subjects</brief_title>
	<detailed_description>This randomize , open-label , six-arm , three-period drug interaction study recruit 48 healthy volunteer obtain minimum 36 evaluable subject single study center U.S . The study screen visit , 3 treatment visit pharmacokinetics ( PK ) sample follow-up visit . The screen visit conduct within 30 day prior receive first dose . Subjects randomize 1 6 treatment group show : Cohort Size Period 1 Period 2 Period 3 Sample Days 1 7 Days 1-14 Days 1-14 A 8 RTG 400mg BID FPV 1400mg BID FPV 1400mg BID - RTG 400mg BID B 8 RTG 400mg BID FPV 1400mg BID FPV 1400mg BID - RTG 400mg BID C 8 RTG 400mg BID FPV 700mg BID FPV 700mg BID - RTV 100mg BID + RTV 100mg BID - RTG 400mg BID D 8 RTG 400mg BID FPV 700mg BID FPV 700mg BID - RTV 100mg BID + RTV 100mg BID - RTG 400mg BID E 8 RTG 400mg BID FPV 1400mg QD FPV 1400mg QD - RTV 100mg QD + RTV 100mg QD - RTG 400mg BID F 8 RTG 400mg BID FPV 1400mg QD FPV 1400mg QD - RTV 100mg QD + RTV 100mg QD - RTG 400mg BID Study subject enter clinic morning prior dose remain center 12 hour follow dose . Fourteen 21 day follow completion third dosing period , study subject return clinic follow-up assessment . The total duration study approximately 86 day screen follow . Blood sample drug concentration measurement amprenavir ( APV ) raltegravir ( RTG ) concentration collect 12 hour end dose period ( 0 [ baseline ] , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 12 hour post-dose ) . Subjects undergo physical examination , CBC differential , HIV test , hepatitis B/C test , liver function test , renal function analysis , lipid panel screening , test except HIV hepatitis B/C repeat follow-up post-study . Adverse event adherence ( pill count medication diary ) assess investigator/study personnel end dose period . Evaluable patient require adhere least 95 % study drug dos . Plasma APV concentration analyze use validate high-performance liquid chromatography method tandem mass spectrometric detection ( HPLC/MS/MS ) plasma RTG concentration triple quadruple mass spectrometry . Plasma APV RTG pharmacokinetic parameter measure include maximum concentration ( Cmax ) , time maximum concentration ( Tmax ) , minimum concentration ( Cmin ) , area concentration-time curve ( AUC ) . All parameter , except Tmax , log-transformed statistical analysis . Analysis variance , consider treatment fix effect subject random effect perform use Statistical Analysis Software ( SAS ) , assume treatment ratio steady-state APV PK parameter 1.0 , 90 % confidence interval within range 0.81-1.24 .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Age &gt; 18 year Adequate renal function ( calculated creatinine clearance via Cockcroft Gault method ( CrCl ) &gt; 50 mL/min ) ; Adequate hepatic function ( total bilirubin &lt; 2.5mg/dL ; hepatic transaminase &lt; 5x normal ) ; Adequate hematologic function ( absolute neutrophil count [ ANC ] &gt; 750 neutrophils/mm^3 ; platelet &gt; 50,000/mm^3 ; hematocrit &gt; 25 % ) ; Nonsmoker Willingness ability adhere treatment followup procedure ; The ability understand sign write informed consent form . They fail meet inclusion criterion Have active infection require parenteral antibiotic hospitalization within 2 week prior enrollment A history document gastrointestinal disease impact drug absorption Are receive medication contraindicate result significant drugdrug interaction RTV ( include , limited , triazolam , astemizole , ergot medication , cisapride , midazolam , bepridil , rifampin ) Have significant document sulfa allergy ( e.g. , StevensJohnson Syndrome ) HIV , Hepatitis B C positive Cigarette/cigar/pipe smoker They pregnant lactate . All woman childbearing potential must use effective method ( ) contraception throughout study participation 30 day follow end study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>Pharmacokinetics study</keyword>
	<keyword>Pharmacokinetics medication</keyword>
</DOC>